CoChat

What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?

Open access
Thewes, Belinda, Meiser, Bettina, Duric, Vlatka M, Stockler, Martin R, Taylor, Alan, Stuart-Harris, Robin, Links, Matthew, Wilcken, Nicholas, McLachlan, Sue Anne, Phillips, Kelly-Anne, Beith, Jane, Boyle, Frances, Friedlander, Michael L · 2005 · The Lancet Oncology
Cited by 66

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND Adjuvant endocrine therapies such as tamoxifen, goserelin, and oophorectomy improve survival for premenopausal women diagnosed with early-stage breast cancer. However, these treatments often result in menopausal symptoms, sexual dysfunction, permanent infertility, or the need to delay pregnancy. We aimed to quantify the survival gains that premenopausal patients with early-stage breast cancer require to justify the side-effects and inconvenience of adjuvant endocrine treatments. METHODS Participants consisted of 102 women who had been diagnosed with early-stage (stage I-II) breast cancer 6-60 months previously, who were aged 40 years or younger at diagnosis, and who had been treated for a minimum of 3 months with endocrine therapy (67 with tamoxifen alone, seven with goserelin alone, and 28 with tamoxifen and goserelin or oophorectomy). 76 patients also received chemotherapy, and 75 received radiotherapy. Participants attended a face-to-face patient-preference interview, in which they were presented with four hypothetical clinical scenarios that were used to quantify the gains in survival rate and life expectancy that women judged necessary to make their endocrine therapy worthwhile. They also completed a questionnaire on standard psychological measures. FINDINGS About half of participants thought that adjuvant endocrine therapy was worthwhile for an absolute gain in survival of 2% from a baseline of either 65% or 85%, and for a gain in life expectancy of 3 months from a baseline of 5 years and of 6 months for a baseline of 15 years. Women who had had more severe endocrine side-effects required larger gains to make endocrine therapy worthwhile (univariate p=0.02, multivariate p=0.04). INTERPRETATION Modest gains in survival are sufficient to make adjuvant endocrine treatment worthwhile for premenopausal women with early-stage breast cancer. Knowing and incorporating what women think should enhance shared decision-making.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(05)70254-0

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 66

Metadata

Authors
Thewes, B., Meiser, B., Duric, V. M., Stockler, M. R., Taylor, A., Stuart-Harris, R., Links, M., Wilcken, N., McLachlan, S. A., Phillips, K.-A., Beith, J., Boyle, F., & Friedlander, M. L.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2005-08
Volume
6
Issue
8
Pages
581-588
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2114744102
Cited by
66
References
4
FWCI
1.81
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? https://app.cochat.ai/papers/10.1016/s1470-2045(05)70254-0
The paper
Thewes, B., Meiser, B., Duric, V. M., Stockler, M. R., Taylor, A., Stuart-Harris, R., Links, M., Wilcken, N., McLachlan, S. A., Phillips, K.-A., Beith, J., Boyle, F., & Friedlander, M. L. (2005). What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? The Lancet Oncology. https://doi.org/10.1016/s1470-2045(05)70254-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.